Focus On Clinical Trial Review Process In China Before Timeline Reform – Merck Exec
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Companies pushing to shorten the clinical trial approval timeline in China should instead focus first on promoting education to improve the review process, according to Merck Clinical Research Operations-Asia Pacific Director Zili Li, who also heads the company's China regulatory policy
You may also be interested in...
Global Trials In China Rich But Challenging – Wyeth Exec
TOKYO - Clinical trials in China have much potential and can be rewarding if pharmaceutical companies are willing to overcome challenges such as working with young researchers in China, who may not have much pharmaceutical experience, said Ling Su, Wyeth vice president of clinical research and development for Asia Pacific
Global Trials In China Rich But Challenging – Wyeth Exec
TOKYO - Clinical trials in China have much potential and can be rewarding if pharmaceutical companies are willing to overcome challenges such as working with young researchers in China, who may not have much pharmaceutical experience, said Ling Su, Wyeth vice president of clinical research and development for Asia Pacific
Industry Should Encourage Clinical Trial Reform In China – Shanghai R&D Panel
SHANGHAI - The pharmaceutical industry should take advantage of China's desire to become a destination of choice for global clinical trials to encourage streamlining of regulatory requirements and expansion of clinical study sites, according to an April 1 panel discussion during the China 2008 Pharmaceutical R&D Summit in Shanghai